HUMANIGEN, INC: Nasdaq/NYSE listing notice — Humanigen receives Nasdaq delisting notice; settles Avid dispute for $3M

HUMANIGEN, INC

Nasdaq notified Humanigen it failed to regain minimum bid price compliance by Feb 20, 2023; not eligible for second extension.
Company also fails stockholders' equity initial listing requirement and market value below $35M for continued listing.
Company intends to request a hearing before Nasdaq Hearings Panel by Feb 28, 2023; stay of suspension pending hearing.
Settled Lenzilumab disputes with Avid Bioservices for $3.0M one-time payment; conditional dismissal after 120 days if no bankruptcy.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

HUMANIGEN, INC received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 21, 2023, the Company received a letter from the Staff of Nasdaq notifying the Company that it had not regained compliance with the minimum bid price requirement as of February 20, 2023 and that it was not eligible for a second 180 day extension period. The Nasdaq Staff’s letter specifically noted that the Company does not comply with the stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The total market value of the Company’s listed securities also remains below the $35 million requirement for continued listing on The Nasdaq Capital Market. The Nasdaq St

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

HUMANIGEN, INC received a nasdaq delisting notice notice regarding stockholders equity.

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity

Exact text from the filing

February 21, 2023, the Company received a letter from the Staff of Nasdaq notifying the Company that it had not regained compliance with the minimum bid price requirement as of February 20, 2023 and that it was not eligible for a second 180 day extension period. The Nasdaq Staff’s letter specifically noted that the Company does not comply with the stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The total market value of the Company’s listed securities also remains below the $35 million requirement for continued listing on The Nasdaq Capital Market. The Nasdaq St

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

HUMANIGEN, INC received a nasdaq delisting notice notice regarding market value.

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value

Exact text from the filing

February 21, 2023, the Company received a letter from the Staff of Nasdaq notifying the Company that it had not regained compliance with the minimum bid price requirement as of February 20, 2023 and that it was not eligible for a second 180 day extension period. The Nasdaq Staff’s letter specifically noted that the Company does not comply with the stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The total market value of the Company’s listed securities also remains below the $35 million requirement for continued listing on The Nasdaq Capital Market. The Nasdaq St

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001214659-23-003011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.